National Institute for Health and Care Research

View the accessible transcript of this podcastCatey Bunce talks to Professor Allan Gaw about the challenges and opportunities presented by #ComplexInnovativeDesign trials from a statistician's perspective.As these trials typically answer multiple research questions, Catey explains why statistician needs to think critically about how to navigate the study so that it answers the questions without increasing the chance of a falsely significant result or even a falsely non significant result.To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trialsThis podcast is part of our pre-pandemic series of podcasts on Complex and Innovative Design (CID) trials. You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.

View the accessible transcript of this podcastSarah Blagden talks to Professor Allan Gaw about why she co-led a paper outlining 10 consensus statements offering guidance to the clinical research community on the design and conduct of Complex Innovative Design (CID) trials.She explains how these types of trials can speed up the drug development pathway and help to clear the backlog of of immuno-oncology drugs that are waiting to be tested, enabling cutting edge treatments can be offered to patients sooner. Sarah also describes why she thinks the UK is ideally positioned to conduct CID studies.To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trials This podcast is part of our pre-pandemic series of podcasts on Complex and Innovative Design (CID) trials. You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.

View the accessible transcript of this podcastEmma Lowe talks to Professor Allan Gaw about the design and delivery of complex and innovative design clinical trials.In this episode they discuss what the term 'complex innovative design' (or CID) means in relation to clinical research. Emma explains that it focuses on 'how the research is done' as opposed to 'why it is being done'. She also highlights some of the benefits of delivering research in new and innovative ways, compared to the traditional randomised controlled trial (RCT).The Life Sciences Sector Deal published on 5 December 2018 sets out the Government’s commitment to consolidate the UK as a world-leader in delivering complex and innovative trials. In relation to this, Emma describes some of the activities undertaken by the National Institute for Health Research (NIHR) to: 1) showcase UK expertise in designing and delivering complex and innovative design trials and; 2) to promote understanding of complex and innovative design trials across the UK clinical research workforce.To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trials This podcast is part of our pre-pandemic series of podcasts on Complex and Innovative Design (CID) trials. You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.